Skip to main content
Press release June 1, 2026

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

Sarepta Therapeutics, Inc. (SRPT)

Press Release « Back 06/01/26 4:30 PM EDT CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Fireside chat: Monday, June 8, at 10:40 a.m. ET Oppenheimer CNS and Neuro-Muscular Summit Investor meetings: Wednesday, June 10, 2026 The presentation for the Goldman Sachs conference will be webcast live under the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us. View source version on businesswire.com: https://www.businesswire.com/news/home/20260601633179/en/ Source: Sarepta Therapeutics, Inc. This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.
View original release